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iNtrODUctiON
Heterozygous gain-of-phosphoinositide 3-kinase (PI3K) 
δ-function mutations in PIK3CD or PIK3R1 cause an autosomal-
dominant primary immunodeficiency (PID) called activated 
phosphoinositide 3-kinase δ syndrome (APDS) or PASLI 
(p110-delta-activating mutation causing senescent T  cells, 
lymphadenopathy, and immunodeficiency) 1 and 2, respectively 
(1–4). The main clinical and immunological characteristics of 
APDS 1 and 2 have been recently described in two major retro-
spective cohort studies (5, 6). Recurrent respiratory infections and 
benign lymphoproliferation emerged as key clinical aspects of the 
disease in both cohorts. Bronchiectasis was noted as a frequent 
complication with 60% in the APDS1 cohort and less frequently 
(18%) in the APDS2 cohort study. Additional immune dysregula-
tion including cytopenias, glomerulonephritis, arthritis, and coli-
tis was reported in these studies. An increased risk for lymphoma 
was also highlighted with 13% among the APDS1 patients and 
28% in the APDS2 cohort. Non-immunological characteristics 
included neurodevelopmental delay (19% of APDS1 and 31% 
of APDS2) and growth impairment, especially among APDS2 
patients (45%). Immunologically, hypogammaglobulinemia with 
increased IgM levels was frequent. B-cell lymphopenia, worsen-
ing with age, and expansion of transitional B cells were the main 
B-cell alterations. A reduction in the frequency of naïve CD4+ 
and CD8+ T cells with an increased frequency of effector/effector 
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Activated phosphoinositide 3-kinase (PI3K) δ Syndrome (APDS), caused by autosomal 
dominant mutations in PIK3CD (APDS1) or PIK3R1 (APDS2), is a heterogeneous primary 
immunodeficiency. While initial cohort-descriptions summarized the spectrum of clinical 
and immunological manifestations, questions about long-term disease evolution and 
response to therapy remain. The prospective European Society for Immunodeficiencies 
(ESID)-APDS registry aims to characterize the disease course, identify outcome pre-
dictors, and evaluate treatment responses. So far, 77 patients have been recruited (51 
APDS1, 26 APDS2). Analysis of disease evolution in the first 68 patients pinpoints the early 
occurrence of recurrent respiratory infections followed by chronic lymphoproliferation, 
gastrointestinal manifestations, and cytopenias. Although most manifestations occur by 
age 15, adult-onset and asymptomatic courses were documented. Bronchiectasis was 
observed in 24/40 APDS1 patients who received a CT-scan compared with 4/15 APDS2 
patients. By age 20, half of the patients had received at least one immunosuppressant, 
but 2–3 lines of immunosuppressive therapy were not unusual before age 10. Response 
to rapamycin was rated by physician visual analog scale as good in 10, moderate in 9, 
and poor in 7. Lymphoproliferation showed the best response (8 complete, 11 partial, 
6 no remission), while bowel inflammation (3 complete, 3 partial, 9 no remission) and 
cytopenia (3 complete, 2 partial, 9 no remission) responded less well. Hence, non-lymph-
oproliferative manifestations should be a key target for novel therapies. This report from 
the ESID-APDS registry provides comprehensive baseline documentation for a growing 
cohort that will be followed prospectively to establish prognostic factors and identify 
patients for treatment studies.
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memory CD8+ T  cells was reported. These first two important 
retrospective analyses of the disease illustrated clinical and 
immunological characteristics but did not address the dynam-
ics of the disease evolution over time. Furthermore, although 
both reports showed that the majority of APDS patients receive 
supportive therapies in terms of immunoglobulin-replacement 
treatment (IGRT) or antimicrobial prophylaxes, data regard-
ing immunosuppressive treatments were only reported for a 
limited number of patients. Here, we use an initial report from 
the European Society for Immunodeficiencies (ESID)-APDS 
prospective registry to address some of these questions.
MetHODs
the esiD-APDs registry:  
Goals and Design
The ESID is a not-for-profit association whose aim is to improve 
knowledge in the field of PIDs (www.esid.org). The ESID Registry 
is an international Internet-based database for basic epidemiologi-
cal (level 1), and more extensive disease-specific (level 3) data on 
patients with PID. The APDS Registry is the first prospective level 
3 project that was initiated to better define the natural history of 
patients with APDS. The study is carried out in accordance with 
the recommendations of Section 15 of the Code of Conduct of the 
General Medical Council of Baden-Württemberg, Germany. The 
protocol was approved by the Ethics committee of the University 
of Freiburg (IRB approval No. ESID registry: 493/14; IRB approval 
No. APDS registry: 458/15). All subjects gave written informed 
consent in accordance with the Declaration of Helsinki. The goals 
of the project are to characterize disease evolution over time, to 
establish prognostic factors and biomarkers, to assess the impact 
of various treatment strategies, and to identify patients who 
could be eligible for novel treatments and interventions. Entry 
into the database requires an initial retrospective documentation, 
followed by yearly prospective follow-ups. Because of required 
patient consent, deceased patients cannot be registered. Each 
patient is evaluated at entry for eligibility by one of the three 
chief investigators to ensure that only patients with functionally 
validated APDS-associated mutations are registered. The APDS 
registry is supported by the pharmaceutical companies Novartis, 
GlaxoSmithKline, and UCB UK, who financed development and 
maintenance of the online level 3-documentation-section for 
APDS as well as project management including ethics submis-
sion in all participating countries, data management, and quality 
controls.
resULts
Disease Manifestations and  
their evolution Over time
By December 2017, 77 patients had been enrolled in the APDS 
Registry, 51 with APDS1, and 26 with APDS2. Detailed clinical 
and immunological information of 68 patients [39 of them not 
published in the cohort papers (5, 6)] from 59 unrelated families 
was available for this initial analysis. Forty-five of these 68 patients 
were diagnosed with APDS1 (43 with the E1021K and 2 with the 
C416R mutation) and 23 with APDS2 (all with mutations leading 
to skipping of exon 11). At the time of evaluation, living patients 
(65) had a mean age of 17.9 years (range 3–47 years). The main 
clinical features reported in APDS1 and APDS2 are summarized 
in Figures 1A,B. As in the previously reported cohorts, recurrent 
respiratory infections were by far the most frequent manifesta-
tion, occurring in 96% of the patients. Upper respiratory tract 
infections, otitis media, and sinusitis were the leading diagnoses, 
and, importantly, 59% of the patients had experienced at least 
one episode of pneumonia. Cumulative retrospective data high-
light that the respiratory infections begin very early in life, with 
almost all patients being affected by the age of 15 (Figure 1C). 
The registry data confirmed the previously described (5, 6) 
high incidence of bronchiectasis (28 patients out of the 55 who 
underwent a CT-scan), which was documented early in life (age 
range: 2–39 years; mean: 11.2 years). As already suggested by a 
previous retrospective review of the literature (7), the majority of 
patients with bronchiectasis had APDS1 (24 patients out of the 
40 who had a CT-scan). Abnormal lung function was noted in 17 
out of 35 patients who performed these tests. Acute viral infec-
tions (with varicella and herpes simplex) as well as chronic viral 
infections/reactivations were frequently documented in APDS1 
and APDS2 patients (Figure 1A). The most frequently reported 
chronic infection in both cohorts was Epstein–Barr virus infec-
tion (16/68). Among the non-respiratory bacterial infections, 
the most frequent was infectious lymphadenitis (14/68). Five 
patients suffered from chronic mucocutaneous candidiasis and 
three developed local infection following vaccination with bacil-
lus Calmette–Guérin. Consistent with the two published cohorts, 
chronic non-neoplastic lymphoproliferation was reported in the 
majority of patients (87%). Persistent peripheral lymphoprolif-
eration, splenomegaly, and lymphoid hyperplasia were frequent 
and they were often concomitantly reported in the same patients 
(Figure  1D). Across the cohort, lymphoproliferation occurred 
with later onset than respiratory infections (Figure  1C) but 
preceded gastrointestinal manifestations and the development of 
autoimmunity.
Benign lymphoproliferation may be difficult to distinguish 
from malignant disease, the risk of which is increased in APDS 
patients. Eight of the registry-documented patients (5 APDS1, 
3 APDS2) developed lymphoma between the age of 11 and 
25 years, including two patients with Hodgkin lymphoma, one of 
whom subsequently developed an intestinal diffuse large B-cell 
lymphoma. Six patients were diagnosed with non-Hodgkin 
lymphomas (two diffuse large B-cell lymphomas, one anaplastic 
lymphoma, one marginal zone lymphoma, two without detailed 
histologic information). Five patients achieved a complete remis-
sion on treatment, one patient achieved only a partial remission, 
one patient was still under treatment at the time of registration, 
while in the remaining case, the lymphoma was sadly fatal. One 
of these eight patients also had a benign ovarian serous cystad-
enoma. One patient developed a B-cell chronic lymphocytic 
leukemia at the age of 40 years. In addition to the established high 
incidence of hematological malignancy, 2 cases of solid organ 
malignancy or pre-malignancy were noted: one case of ductal 
breast carcinoma-in situ (diagnosed in an APDS2 patient at the 
FiGUre 1 | (A) Incidence of infections in APDS1 and APDS2 patients. (B) Incidence of manifestations of immune dysregulation in APDS1 and APDS2 patients. 
(c) Evolution of disease manifestations over time. Information regarding age at onset available for: respiratory infections n = 62/65, lymphoproliferation n = 59/59, 
gastrointestinal manifestations n = 33/35, cytopenia n = 20/21 patients. (D) Diagram showing the different types of benign lymphoproliferative manifestations. 
(e) Diagram showing the different blood lineages affected in patients with cytopenias.
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age of 33) and one case of rhabdomyosarcoma (diagnosed in an 
APDS1 patient at the age of 13).
Gastrointestinal manifestations were the third most frequent 
disease manifestation (51%) and across the cohort occurred 
before the other features of immune dysregulation, such as cyto-
penias or arthritis, but typically much later than the respiratory 
infections and the benign lymphoproliferation (Figures 1B,C). 
Small or large bowel inflammation was histologically confirmed 
in 17 patients, in 11 of them by the age of 10 years. Granulomas 
were reported in only one patient. Protracted diarrhea with no 
identified underlying cause was the second commonest reported 
gastrointestinal problem and was often severe enough to require 
hospitalization. Two patients were diagnosed with autoimmune 
hepatitis but no cases of sclerosing cholangitis were reported, in 
contrast with the two patients reported by Coulter et al. (5) and the 
two reported by Hartman et al. (8). Of note, 14/68 patients of the 
APDS-Registry cohort had eczema. Elkaim et al. (6) noted only 
three APDS2 patients with chronic eczema and no inflammatory 
skin disease was mentioned in the published APDS1 cohort (5). 
Cytopenias were the fourth major disease manifestation affecting 
around 30% of patients, usually later in life (Figures 1B,C) than 
the other main features and frequently affecting multiple blood 
lines (Figure 1E). The autoimmune origin of the cytopenias could 
be documented in the majority of the patients. Other autoim-
mune diseases were also reported, all occurring after the age of 
10  years: two patients had autoimmune thyroiditis, three had 
arthritis, and three glomerulonephritis.
Concerning non-immunological manifestations, short stature 
(>2 SD) was reported in 11 patients, with a predominance of 
APDS2 individuals (8/13), consistent with previous reports (6, 
7). Neurodevelopmental delay was diagnosed in three patients. 
Specific neuropsychiatric disorders were also reported: one 
patient had Asperger Syndrome, one had autism, one suffered 
from a mixed anxiety and depression disorder, and two other 
FiGUre 2 | (A) Use of treatment modalities over time. IGRT, immunoglobulin-replacement-treatment; IS, immunosuppressive drug; HSCT, hematopoietic stem cell 
transplantation. Information regarding age at first therapy available for: IGRT n = 28/44, steroid therapy n = 31/31, IS therapy n = 35/36, HSCT = 8/8. (B) Number 
of lines of immunosuppressive treatments (steroids, immunosuppressive drugs, rituximab) by the time of registration; red: patients who had undergone HSCT by the 
time of registration. (c) Response to rapamycin treatment. White: complete response; gray: partial response; black: no response; red: worsened or new 
manifestation; boxes with a diagonal: manifestation not present in this patient. CR, complete remission; PR, partial remission. Rapamycin stopped because of: 
*non-compliance, °inefficiency, ^side effects, §clinical trial. (D) Overall clinical benefit (Visual Analog Scale) according to physician’s evaluation.
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patients had mild disorders of speech and language development. 
It is unclear if these findings reflect the impact of a severe physical 
illness or the impact of enhanced PI3Kδ signaling in the central 
nervous system.
immunological Abnormalities
One of the objectives of the ESID-APDS registry is to collect 
immunological data prospectively. An initial analysis of the 
immunological profile in the registry cohort confirmed the 
already published T- and B-cell alterations. No clear difference 
between APDS1 and 2 was detected in the current cross-
sectional data set. In the future, the longitudinal collection 
and analysis of these data will offer the possibility to explore 
associations between specific disease manifestations and immu-
nological alterations, to evaluate the response of immunological 
alterations to the different types of treatment, and to establish 
the predictive value of immunological parameters for disease 
prognosis.
current therapies
Supportive therapy is a key component of the management of APDS 
patients. In the APDS-registry, 54 patients received antibiotic proph-
ylaxis, whereas only eight received antifungal prophylaxis, which 
appears justified given the absence of reported invasive fungal infec-
tions. IGRT was administered in 44 patients (28/45 APDS1, 16/23 
APDS2), was in general very well tolerated, and was started early in 
life (Figure 2A), mirroring the early presentation with respiratory 
infections. The majority of patients also received immunosuppres-
sive treatments. Thirty-one patients received corticosteroids and 27 
of them showed at least a partial clinical benefit. More than half 
6Maccari et al. The ESID-APDS Registry
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had received steroid treatment by the age of 20 (Figure 2A). Thirty-
six patients received other immunosuppressive drugs, including 
azathioprine (n = 1), mycophenolate (n = 3), cyclosporine (n = 5), 
or rapamycin (n = 27); clinical benefit was reported in 28 of these 
patients. Rituximab was given to eight patients, with clinical benefit 
in all. Figure 2B illustrates the multiple lines of immunosuppres-
sive treatments (steroids, immunosuppressive drugs, or rituximab), 
which had already been received by patients by the time of enroll-
ment into the registry. Five patients underwent splenectomy (4 
APDS1 and 1 APDS2) because of cytopenias or splenomegaly and 
25 patients (12 APDS1 and 13 APDS2) underwent tonsillectomy 
(age range: 1–12 years), with clear benefit in only seven of them. 
The only available curative option is hematopoietic stem cell trans-
plantation (HSCT) and the first experiences in this field have been 
published (9). Among the patients in the registry, 8/68 patients had 
undergone HSCT (7 APDS1 and 1 APDS2) by the time of registra-
tion (Figure 2A), with fatal outcome in one.
rapamycin therapy in APDs
Consistent with activation of mTOR signaling downstream of the 
activated PI3Kδ, patients with APDS may benefit from rapamycin 
(2). In the APDS2 cohort-paper (6), six patients had been treated 
with rapamycin, but the time of follow-up was too short to evaluate 
the response to treatment in four of them. Six of the patients in the 
reported APDS1 cohort (5) were treated with rapamycin for benign 
lymphoproliferation; five of them had a treatment response, but in 
one case, the therapy was stopped due to side effects. Additional 
case reports of rapamycin therapy have also been published (7, 10). 
In the ESID-APDS-registry cohort, rapamycin was the most fre-
quently used immunosuppressive drug. We, therefore, decided to 
evaluate the experience with rapamycin (Sirolimus) in 26 patients 
(1 patient was not included because treatment was started and 
terminated before the diagnosis of APDS and the response to 
therapy was not well documented), 17 with APDS1, and 9 with 
APDS2. The main indications for treatment were lymphoprolif-
eration, colitis, and/or cytopenia. Physicians were asked to judge 
the degree of severity of each manifestation as mild, moderate, or 
severe at the start of therapy, following 3–6 months of treatment 
and at the latest follow-up (average time of therapy monitoring: 
1.6 years). Overall response judged by the physician visual analog 
scale was good in 10, moderate in 9, and poor in 7 (Figure 2D). 
Lymphoproliferation showed the best response (8 complete, 11 
partial, 6 no remission), while bowel inflammation (3 complete, 3 
partial, and 9 no remission) and cytopenia (3 complete, 2 partial, 9 
no remission) responded less well, as shown in Figure 2C. Notably, 
of the eight patients who were on steroids at initiation of treatment 
with rapamycin (No. 1, 7, 9, 13, 19, 22, 23, 25), seven were able to 
stop steroids and one (No. 25) was able to reduce the dose. Two 
patients (No. 4, 5) stopped therapy because of poor compliance, 
in three cases (No. 6, 14, 15), the reason for cessation was lack of 
efficacy. Two patients (No. 7, 13) suffered from side effects (severe 
headaches, anorexia, renal toxicity) that led to the complete inter-
ruption of the treatment, whereas in three cases, the therapy was 
paused because of side effects (aphthous ulcers, liver toxicity, renal 
toxicity) but could be started again. Two patients (No. 3, 8) stopped 
despite efficacy because of enrollment in a clinical trial with PI3Kδ 
inhibitors. In two other individuals (No. 11, 12), treatment was 
interrupted after prolonged usage; in one patient (No. 20), this was 
due to the patient planning for pregnancy and, in another (No. 
19), it followed the development of a lymphoma. Of note, three 
patients (No. 14, 18, 25) received also Rituximab during and one 
(No. 10) shortly before the treatment with rapamycin. One patient 
(No. 20) concomitantly received Adalimumab because of arthritis. 
Interestingly, some patients did not show any relevant alterations 
in the disease manifestations after 3–6 months of therapy but did 
show either improvement (No. 1, 8, 10, 18, 22, 23) or worsening 
(No. 6, 14, 19) after a longer period of observation on treatment 
(about 2 years).
DiscUssiON
We present an initial analysis of the prospective ESID-APDS 
registry, a longitudinal cohort study of patients with APDS1 and 
APDS2. This overview expands the known information regarding 
the clinical manifestations of the disease by adding the aspect of 
the evolution of the features over time. The emerging picture is 
the one of a PID characterized by the early occurrence of respira-
tory infections (mostly upper respiratory infections), followed 
by the development of chronic benign lymphoproliferation and 
subsequently other features of immune dysregulation, in particu-
lar, gastrointestinal manifestations and autoimmune cytopenias. 
We again noted the higher incidence of bronchiectasis in APDS1 
compared with APDS2 patients; however, the numbers remain 
small and differences in CT uptake cannot be excluded as a con-
founder. However, this observation may stimulate future studies 
of the roles of the PIK3CD and PIK3R1 genes and their proteins 
in the respiratory system. In the future, further analysis of the 
clinical evolution in this prospective cohort will allow better 
definition of long-term prognosis for this disease. In addition, 
the correlation of clinical features with the immunological abnor-
malities and their relationship with outcome parameters will help 
defining clinical and biological biomarkers of outcome.
The choice of treatment is a key issue in these patients who 
often present with severe concomitant manifestations not only of 
immunodeficiency but also of immune dysregulation. According 
to the registry, the combination of supportive therapy to prevent 
recurrent infections and the immunosuppressive treatment of 
immune dysregulation is often initiated early in life, with many 
patients undergoing multiple treatments. Rapamycin inhibits the 
biologically relevant downstream PI3K effector mTOR pathway, 
and it has been widely used with good efficacy in other PIDs, 
in particular, autoimmune lymphoproliferative syndrome (11, 
12). Our interrogation of the ESID-APDS registry aligns with 
previous reports (7, 10) in suggesting that rapamycin reduces 
the severity of benign lymphoproliferative disease also in APDS. 
However, a less satisfactory response was documented regarding 
the non-lymphoproliferative manifestations, in particular, intes-
tinal disease and cytopenias, which can be highly detrimental 
for the patients’ quality of life. It is important to relate these 
registry results to the first results of targeted therapy with the 
PI3Kδ inhibitor leniolisib that have recently been published (13). 
In the first six patients, the drug showed an excellent control of 
the lymphoproliferation (6/6 patients) and in part also improved 
the cytopenias at the end of treatment (day 84). Three of the 
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six patients normalized their thrombocytopenia, one patient 
resolved his anemia, and three of four patients improved their 
lymphopenia, while there was no correction of the neutropenia 
observed in two patients; however, respiratory and gastrointes-
tinal symptoms and outcomes were not reported in this study. 
Furthermore, our registry analysis highlighted that also colitis 
and skin disease can cause significant symptoms in these patients 
and should, therefore, be carefully evaluated in future clinical 
studies on novel therapies, particularly given previous reports 
of colitis associated with PI3K inhibitors (14). Longitudinal data 
capture on APDS patients in the ESID-APDS registry will be 
critical to observe the long-term benefits and/or side effects of 
these therapies, in particular, their effect on the incidence of lym-
phomas. It is noteworthy that one patient developed lymphoma 
while taking rapamycin. Another key question, where the registry 
will be helpful, is the question if and when to perform HSCT. The 
analysis of this question will profit from the principles established 
in the P-CID study, a prospective natural history study on pro-
found combined immunodeficiency in which matched pairs of 
transplanted and non-transplanted patients with similar disease 
burden and immunological alterations are followed (15).
Finally, an attractive goal for the registry is to involve patients 
and their families directly in data acquisition. This could in the 
future allow collecting information about the quality-of-life of 
APDS patients, thus ameliorating the evaluation of the disease 
burden in all its complexity. In summary, thanks to the collabora-
tive work of the participating centers, the ESID-APDS registry 
will comprise a valuable resource for physicians dealing with this 
disease and for shaping future research questions.
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